Industry Involvement in FSHD Research
The FSHD CTRN is committed to building symbiotic relationships with industry to advance the development of FSHD therapies. Relationships thus far have included consults for study concept and design, and collecting new outcome assessments to support phase II/III drug development - both essential to expedite therapeutic development. We welcome the opportunity to work closely with industry experts to optimize the therapy development pathway.
- Consult for protocol development
- Site selection services
- Conduct trials
- Develop study-related materials
- Provide opportunities to interact with academic researchers and patient advocates
- Organize key opinion leader conferences
Clinical Trials
View all Facioscapulohumeral Muscular Dystrophy related clinical trials in the state of Kansas.